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Abstract Neoadjuvant chemotherapy for breast cancer
allows individual tumor response to be assessed depending
on molecular subtype, and to judge the impact of response
to therapy on recurrence-free survival (RFS). The multi-
center I-SPY 1 TRIAL evaluated patients with C3 cm
tumors by using early imaging and molecular signatures,
with outcomes of pathologic complete response (pCR) and
RFS. The current analysis was performed using data from
patients who had molecular profiles and did not receive
trastuzumab. The various molecular classifiers tested were
highly correlated. Categorization of breast cancer by
molecular signatures enhanced the ability of pCR to predict
improvement in RFS compared to the population as a
whole. In multivariate analysis, the molecular signatures
that added to the ability of HR and HER2 receptors, clin-
ical stage, and pCR in predicting RFS included 70-gene
signature, wound healing signature, p53 mutation
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signature, and PAM50 risk of recurrence. The low risk
signatures were associated with significantly better prog-
nosis, and also identified additional patients with a good
prognosis within the no pCR group, primarily in the hor-
mone receptor positive, HER-2 negative subgroup. The
I-SPY 1 population is enriched for tumors with a poor
prognosis but is still heterogeneous in terms of rates of
pCR and RFS. The ability of pCR to predict RFS is better
by subset than it is for the whole group. Molecular markers
improve prediction of RFS by identifying additional
patients with excellent prognosis within the no pCR group.
Keywords Breast cancer  Neoadjuvant chemotherapy 
Molecular biomarkers  Pathologic complete response
Introduction
Molecular and genetic studies demonstrate that breast
cancer is a heterogeneous disease. Several classifiers are
available for distinguishing tumor types based on prognosis
and prediction of response to chemotherapy and hormonal
therapy [1–3]. Molecular features are associated with
substantially different outcomes [4] and with wide vari-
ability in response to standard therapies [5, 6]. Symptom-
atic tumors that tend to be large and palpable on
presentation have substantially higher risk of recurrence
than tumors detected by screening [7]. For these larger
tumors, neoadjuvant, or preoperative, chemotherapy makes
it possible to assess response to treatment and may provide
insights to the tumor’s biology. Studies examining the
degree to which pathologic complete response (pCR) to
therapy is predictive of recurrence-free survival (RFS) or
overall survival (OS) have given mixed results in relatively
unselected populations [8–12].
The I-SPY 1 TRIAL (investigation of serial studies to
predict your therapeutic response with imaging and
molecular analysis) is a multicenter neoadjuvant study of
women with histologically confirmed invasive breast can-
cers. This report describes associations between molecular
markers assessed in pretreatment tumor biopsy samples and
response to neoadjuvant chemotherapy at the time of sur-
gery, longer-term disease outcomes, and the relationship
between response and RFS.
Methods
Study design and patient selection
The I-SPY 1 TRIAL methods have been described in detail
elsewhere [13, 14] and was a collaboration of the American
College of Radiology Imaging Network (ACRIN), Cancer
and Leukemia Group B (CALGB), and Specialized pro-
grams of research excellence (SPORE). All patients gave
written consent and had histologically confirmed invasive
breast cancers measuring at least 3 cm by clinical exami-
nation or imaging, with no evidence of distant metastatic
disease. Patients’ clinical stage 1 by exam was eligible if
tumor size was [3 cm by imaging. Patients with T4 or
inflammatory disease were eligible. The regimen of neo-
adjuvant chemotherapy included an initial anthracycline-
based regimen after which patients either underwent sur-
gery or received a taxane-based regimen prior to surgery.
Assays were conducted in nine laboratories. Data was
integrated for central accession for analysis using NCICB’s
caINTEGRATOR application (https://caintegrator-stage.nci.
nih.gov/ispy/index2.jsp)—I-SPY 1 data version dated Feb-
ruary 2011.
Standard pathology biomarkers
Hormone and HER2 receptor expression were measured
from pretreatment core biopsies. Estrogen and progester-
one receptor status were determined by immunohisto-
chemistry (IHC) and calculation of Allred scores [15] at the
study sites. HER2 status was determined locally by IHC
and/or fluorescence-in situ hybridization assays (FISH).
HER2 testing (IHC and FISH) was also performed cen-
trally at the University of North Carolina (UNC) [13, 16].
HER2 status was considered positive if either local or
central assays were positive. Ki67 was recorded as low
(\10%), medium (10–20%), or high ([20%) and described
in detail in supplemental methods [17].
Evaluation of pathologic response
pCR is defined as no invasive tumor present in either breast
or axillary lymph nodes. Residual Cancer Burden (RCB)
[9] was assessed and included the primary tumor bed area,
overall invasive cancer and in situ disease cellularity,
number of positive lymph nodes and diameter of largest
metastasis. I-SPY 1 TRIAL pathologists were centrally
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trained; all cases were re-reviewed and scored for RCB as a
dichotomous outcome (0, I vs. II, III) and by class (0, I, II,
III). Data was recorded using NCI’s Oracle Clinical
Remote Data Capture version 4.5 electronic database.
RNA analysis
Tissue samples immediately frozen in OCT were assayed
on catalog 44,000 feature Agilent Human oligonucleotide
microarrays (catalog # G4112F). Total RNA purification
and microarray hybridization were done as previously
described [18]. The background was subtracted and Low-
ess normalized log2 ratio of Cy3 and Cy5 intensity values
were calculated [19]. The primary microarray data pre-
sented in this study are available in the GEO database
under accession number GSE22226.
Intrinsic subtype classification was determined by
PAM50 50-gene assay as described [18]. The risk of
recurrence score (ROR-S) classified patients as having
high, medium, or low risk of relapse using predefined cut-
points as described previously [19].
The 70-gene prognostic profile was determined using
representative probes and data normalization as previously
described [20]. This profile classified patients as having
high or low risk of relapse using the predefined threshold
[20, 21].
Wound healing signature [22] was used to classify
tumors as quiescent or activated. A gene-expression sig-
nature predictive of p53 genotype [23] was used to classify
tumors as p53 wild type or mutated.
DNA analysis
DNA copy number abnormality was assessed by a
molecular inversion probe (MIP) platform with focal
amplification and high resolution (*10 K bp) as previ-
ously described [24–26]. Direct p53 genotyping was per-
formed and mutations were detected by the Roche p53
AmpliChip beta test array [27, 28] and a combination of
two approaches described in supplemental methods.
Statistical analysis
The primary endpoint for the trial was RFS according to
the STEEP criteria [29]. Time to recurrence was computed
from start of treatment; and RFS at 3 years was determined
by Kaplan–Meier analysis.
Associations of signature classifications with pCR and
RFS were assessed by logistic regression and proportional
hazards modeling, respectively. Association of pCR with
RFS within each risk subset was also tested. These analyses
were conducted using JMP Version 8.0.1, SAS Institute
Inc.
We took HR/HER2 categories to be standard and addressed
the ability of other signatures to predict RFS and pCR
assuming HR/HER2 category is given. We used multivariate
Cox regression of RFS on molecular signature classification,
adjusting for the predefined contribution of HR and HER2 (as
derived from a Cox model fit of RFS on HR and HER2).
Similarly, we employed multivariate logistic regression to
evaluate whether other molecular signature classifications
were independently predictive pCR when given HR/HER2.
These analyses were conducted using Bioconductor R [30].
Differences in rates of pCR and rates of RCB class 0 or
1 within molecular signature-defined subgroups were
assessed by v2 tests.
Patient were categorized as low- or high-risk by each
molecular signature HR?/HER2- versus others, luminal
(A and B) versus others (HER2-enriched, basal, and nor-
mal-like) [31], p53 wild type versus mutation, 70-gene
prognosis signature low versus high [20], and wound-qui-
escent versus wound-activated [22], and stage 3 (including
inflammatory) versus earlier stage to ensure comparable
degrees of freedom. The pairwise concordances of the
molecular signatures were compared by Kendall’s rank
correlation and Fisher’s exact test.
All statistical analyses were performed (CY) and veri-
fied by a second statistician (DB) to confirm the results.
Results
Patient characteristics
Between May 2002 and March 2006, 237 patients were
enrolled at nine institutions as described previously [13].
As shown in the CONSORT diagram (Fig. 1), 221 patients
received an anthracycline as initial neoadjuvant chemo-
therapy, with 95% receiving a taxane, and were considered
evaluable. Of these, 215 (97%) underwent surgical resec-
tion and had pathologic data available for analysis; IHC
receptors were available for 210 and RCB was available for
196 (93%). We attempted microarrays on all 210 patients
but could generate high quality gene-expression arrays for
just 149 (Fig. 1). In addition, 171 patients had p53 gene
mutation chip data and 153 had copy number variation by
MIP arrays. Patients with available gene-expression arrays,
who did and did not receive trastuzumab, were not sig-
nificantly different from the overall cohort (Table 1).
Among the 215 patients, 20 of 67 (30%) HER2?
patients received neoadjuvant trastuzumab, as previously
described [13]. Of the 46 HER2? patients who did not, 17
(36%) received adjuvant trastuzumab. Radiation and hor-
monal adjuvant therapy were also given at physician dis-
cretion as clinically indicated (Table 1). Analysis of RFS
was limited to patients who did not receive trastuzumab.
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Most (65%) patients had clinically or pathologically
confirmed axillary lymph node involvement at diagnosis
and 90% had tumors of intermediate or high histologic
grade. Median follow-up for survival and RFS was
3.9 years.
Early outcomes: residual disease measured at the time
of surgical resection
The overall rate of pCR was 27%, and the rate of RCB
scores of 0 or I was 37%.
As shown in Table 2, the response to therapy varied
considerably by marker subset. For the subsets defined by
clinical assay (IHC markers), pCR rates were lowest for the
HR?/HER2- subset (9%) and highest for the HR-/
HER2? subset (54%). Of the PAM50 intrinsic subtypes,
pCR rates were lowest for luminal A (3%) and highest for
HER2-enriched population (50%). For Ki67, the pCR rates
varied from 5% for the low group to 35% for the high
group. Other biomarkers were associated with high rates of
pCR, including p53 null mutations by Gene Chip (47%)
and amplification at 17q as measured by MIP array (45%).
The rates of pCR and RCB scores of 0 or I for four gene-
expression prognostic classifiers—70-gene prognosis signa-
ture, ROR-S, wound healing, and p53 mutation signatures—
were all low (Table 2). In this population of patients treated
with neoadjuvant chemotherapy, a minority of patients had
good prognosis profiles: 9% were classified as 70-gene low
risk, 27% as ROR-S low, 25% as wound healing quiescent,
and 49% as p53 wild type. The respective pCR rates were 0, 6,
7, and 9%. Rates of pCR were higher for poor prognosis sig-
natures, including 70-gene high risk (24%), wound healing
signature activated (26%), ROR-S moderate risk (17%) and
high risk (36%) and p53 mutation predicted by expression
profile (34%). Clinical outcomes were better when pCR or an
RCB score of 0 or 1 was achieved.
Recurrence-free and OS
Three-year RFS and OS for the entire cohort were 78 and
85%, respectively. When RFS for the population was
stratified by molecular signatures, outcomes by subtype
differed substantially (Table 2).
We dichotomized the classifiers, using low versus
medium and high for the analyses shown in Tables 3 and 4.
Although developed using heterogeneous methods and
populations, dichotomized tumor classifiers and signatures
were highly correlated, with concordances generally[70%
(Table 3). As shown in Table 4, for the breast cancer
subtypes known to be associated with a better outcome
(e.g., luminal, 70-gene low risk, wound healing quiescent,
and p53 wild type), the RFS was relatively high for patients
who did not achieve pCR, but pCR was associated with a
better outcome, regardless of subtype. Poor prognosis
tumors tend to be more sensitive to chemotherapy, and thus
have a higher rate of pCR. The hazard ratio for the pre-
diction of pCR versus not was better within the dichoto-
mized molecular classifications than for the population as a
whole. Associations between RFS and pCR differed the
most for HR?/HER2- versus not (hazard ratio 0.17, [95%
CI 0.04–0.51]), which was also where rates of pCR differed
the most (9 vs. 38%). For the dichotomized breast cancer
molecular classifiers (Table 4), the difference between
highest and lowest rates of pCR varied from 19 to 29%.
In a multivariate model, the factors that added to HR and
HER2 in predicting RFS were clinical stage (stage 3 vs. not),
wound healing (activated vs. quiescent), ROR-S, and pre-
dicted p53 mutation signature (Table 5). The only factor that
added to HR and HER2 in predicting pCR was Ki67 low and
medium versus high (data not shown). The analysis shown
was performed using the dichotomized groupings for the
molecular signatures, but the results were qualitatively the
same when the original groupings were used (data not shown).
When receptor status and pCR were fixed in a multi-
variate model, most molecular signatures and clinical stage
improved the ability to predict RFS (data not shown). The
most likely reason is because the molecular classifiers can
identify additional patients in the ‘‘no pCR’’ group who
have excellent outcomes, the majority of whom are in the
Fig. 1 CONSORT diagram: patients available for analysis. Of the
237 patients enrolled in the study, 16 patients withdrew. Of the 221
patients available for analysis, six decided not to undergo surgery
after completing neoadjuvant chemotherapy, leaving 215 patients
available for pathologic response analysis
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Table 1 Demographics and characteristics of patients in the I-SPY 1 TRIAL
Characteristics I-SPY trial
evaluable
(n = 221)
Profiled with
agilent
microarray (n = 149)
Profiled with agilent
microarray without any
trastuzumab (n = 120)
Age (years)
Median (range) 49 (26–68) 48 (27–65) 47 (28–65)
Premenopausal 48% (106) 49% (72) 47% (56)
Race
Caucasian 75% (165) 76% (114) 77% (93)
African American 19% (42) 18% (27) 18% (21)
Asian 4% (9) 5% (7) 4% (5)
Other 2% (5) 1% (1) 1% (1)
Clinical tumor size (cm)
Median (range) 6.0 (0–25) 5.5 (0–25) 5.5 (0–18)
Tumor longest diameter on baseline MRI (cm)
Median (range) 6.8 (0–18.4) 6.5 (0–18.4) 6.45 (2.0–16.6)
Clinically node positive at diagnosis 65% (143) 66% (99) 63% (76)
Histologic grade (baseline)
Low 8% (18) 7% (10) 7% (9)
Intermediate 43% (96) 42% (63) 40% (48)
High 47% (103) 50% (75) 52% (62)
Indeterminate 2% (4) 1% (1) 1% (1)
Clinical stage (baseline)
I 1% (3) 2% (3) 2% (3)
IIA 19% (43) 21% (32) 25% (30)
IIB 28% (61) 26% (38) 26% (31)
IIIA 35% (78) 34% (51) 33% (40)
IIIB 5% (11) 5% (8) 7% (8)
IIIC 3% (7) 3% (5) 2% (2)
Inflammatory 8% (17) 7% (11) 4% (5)
Indeterminate \1% (1) 1% (1) 1% (1)
Hormone receptors (baseline)
ER-positive 56% (124) 55% (82) 58% (70)
PR-positive 46% (102) 44% (66) 49% (59)
HR-positive (ER or PR) 59% (130) 58% (86) 62% (74)
Her-2 positive (baseline) 30% (67) 30% (45) 15% (18)
HR-negative/Her-2 negative (baseline) (triple negative) 24% (53) 25% (37) 30% (36)
Neoadjuvant treatment
AC only 5% (11) 3% (4) 3% (4)
AC ? T 85% (187) 87% (129) 95% (114)
AC ? T ? trastuzumab 9% (20) 9% (14) –
AC ? T ? other 1% (3) 1% (2) 1% (2)
Surgery type
Mastectomy 56% (123) 57% (84) 54% (65)
Lumpectomy 41% (92) 40% (60) 43% (51)
No Surgery 3% (6) 3% (5) 3% (4)
Post-operative adjuvant therapy 58% (128) 56% (84) 45% (54)
Any hormonal therapy 34% (75) 34% (52) 38% (46)
Tamoxifen 43% (95) 44% (61) 43% (52)
Aromatase inhibitor 12% (27) 12% (20) 12% (15)
Breast Cancer Res Treat (2012) 132:1049–1062 1053
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HR?/HER2- receptor subtypes. The Kaplan–Meier plots
for the hormone receptor positive patients without a pCR,
stratified by four of the molecular signatures, and by
clinical stage, showed that the low risk classification
identified patients with a much better outcome than the
high risk classification (Fig. 2).
A visual representation or unsupervised cluster of the
clinical features of the patients in I-SPY 1 who did not receive
trastuzumab is shown in Fig. 3. Like Table 3, this figure
illustrates the high degree of overlap among clinical variables
and molecular signatures. There is a cluster of tumors with
many high risk features illustrated by the cluster in red in the
lower left, some with pCR and good outcomes and without
pCR and poor outcomes, but the molecular features of these
tumors are the same and do not appear to provide information
to discriminate between good and poor outcomes.
Discussion
The I-SPY 1 collaboration demonstrates that standards for
imaging, data and tissue collection can be followed and
molecular profiling from small specimens is achievable.
Molecular profiles were generated for over 65% of all
patients (improving as the trial proceeded), and these
patients are representative of the entire data set.
Patients who present with large breast tumors, as
exemplified by the I-SPY 1 cohort, have biologically poor-
risk cancers, as evidenced by 91% having 70-gene high risk
profile and the fact that many are interval cancers [32].
Even within this clinically high risk population, response to
therapy was heterogeneous. HER2 positivity and HR neg-
ativity were associated with a greater rate of pCR, as were
four poor prognosis molecular signatures: wound-activated
signature, ROR-S high risk, 70-gene poor-risk, and p53
predicted mutation. Patients with good prognosis signa-
tures had a lower chance of short-term (pCR, RCB)
response to chemotherapy, but had better long-term (RFS,
OS) outcomes, even when their tumors did not respond to
therapy. These findings support the emerging consensus
that patients with good risk signatures (wound healing
quiescent, 70-gene low, and ROR-S low) have low rates of
early recurrence in spite of large tumor size. The molecular
profiles vary by the percent of the population they classify
as low risk, the fraction that respond to therapy, and the
outcomes among those without pCR, even though the data
set was not sufficiently large to show a statistical
difference.
The International Breast Cancer Study Group (IBCSG),
NSABP, and MD Anderson Cancer Center [33] have found
that pCR rates are much higher in patients with HR-neg-
ative tumors than in those with HR-positive tumors. These
Table 1 continued
Characteristics I-SPY trial
evaluable
(n = 221)
Profiled with
agilent
microarray (n = 149)
Profiled with agilent
microarray without any
trastuzumab (n = 120)
Ovarian suppression or ablation 3% (7) 3% (6) 4% (5)
Trastuzumab 16% (35) 16% (25) –
Institutions participating in the I-SPY trial
Total accrual 237
Institution name Accrual Biomarker tests performed*
Georgetown University Hospital 4
Memorial Sloan-Kettering Cancer Center 20
National Cancer Institute/George Mason University N/A Reverse phase phosphoprotein arrays
University of Alabama at Birmingham 50
University of California, San Francisco 67 Frozen tissue, DNA and RNA processing, cDNA arrays
University of Chicago 2
University of North Carolina 38 Paraffin-based IHC; p53 gene chip; expression profiling
University of Pennsylvania Medical Center 36 Paraffin-based IHC
University of Texas, Southwestern 14
University of Washington, Seattle 6
ER estrogen receptor, PR progesterone receptor, AC anthracycline, T trastuzumab
* All sites performed testing for estrogen receptor (ER), progesterone (PR), and human epithelial growth factor receptor 2 (HER2). Frozen tissue
was stored at the University of California, San Francisco; formalin-fixed, paraffin-embedded at the University of North Carolina; and blood at
CALGB Pathology Central Office at Ohio State University
1054 Breast Cancer Res Treat (2012) 132:1049–1062
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Table 2 Distribution and response rates by molecular phenotypes and profiles
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observations are consistent with our results and with
adjuvant studies that show patients with HR-negative dis-
ease benefit more from chemotherapy [34] than do patients
with HR-positive disease.
Molecular profiles may provide the opportunity to
identify, beyond HR and HER2 status, what might be
driving tumor behavior and outcomes. In a multivariate
model, when receptor types were fixed, the factors that
added to RFS included clinical stage, wound healing
signature, ROR-S, and p53 predicted mutation. When pCR
was also fixed, most of the dichotomized molecular
markers added some additional predictive value, likely
because of the ability to identify patients in the ‘‘no pCR’’
group who have excellent outcomes, largely the HR?/
HER2- subgroup, though not exclusively. Given that the
low proliferative HR? subset is at risk for late recurrence,
longer follow-up and additional studies will be required to
validate this observation.
Table 2 continued
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Table 3 Correlations among the molecular signatures
Correlation coefficient
Concordance (P value)
p53 wt 70-Gene low Luminal Wound-quiescent ROR-S low
HR?, HER2- 0.44 0.26 0.62 0.34 0.40
0.72 0.63 0.81 0.68 0.71
(\0.001) (0.002) (\0.001) (\0.001) (\0.001)
p53 wt + 0.32 0.65 0.55 0.56
) 0.59 0.83 0.73 0.74
(\0.001) (\0.001) (\0.001) (\0.001)
70-Gene low + 0.33 0.41 0.54
) 0.61 0.82 0.83
(\0.001) (\0.001) (\0.001)
Luminal + 0.40 0.55
) 0.68 0.75
(\0.001) (\0.001)
Wound-quiescent + 0.63
) 0.86
(\0.001)
HR hormone receptor, wt wild type, ROR-S risk of relapse score. Signatures are shown as dichotomies: HR?/HER2- vs. not, luminal (A and B)
vs. the other intrinsic subtypes (HER2 enriched, basal, and normal-like), p53 wild type vs. mutation, 70-gene prognosis low vs. high (only 13
(9%) patients are in the low risk prognosis group), and wound-quiescent vs. wound-activated. Concordance refers to the lower risk subsets
Table 4 Pathological complete response and recurrence-free survival by molecular subtypes
Pathological complete response (pCR) Recurrence-free survival
Rate of pCR (n) Odds ratio
(P value)
Hazard ratio
(95% CI)
Hazard ratio, pCR vs. no PCR
(95% CI within subgroup)
All patients with surgery 27% (215) – – 0.41* (0.18–0.82)
Population without any trastuzumab 22% (180) – – 0.23 * (0.06–0.63)
HR?/HER2- (Yes vs. other) Yes: 9% (8/93) 0.15
(\0.001)
0.50*
(0.27–0.89)
Yes: 0.00 (–)
Other: 38% (30/79) Other: 0.17* (0.04–0.51)
p53 (Wt vs. Mut) Wt: 9% (5/58) 0.18
(\0.001)
0.34*
(0.15–0.69)
Wt 0.00 (–)
Mut: 34% (20/58) Mut: 0.22* (0.05–0.65)
70-Gene (low vs. high) Low: 0% (0/11) 0.00
(0.02)
0.00*
(–)
Low: 0.00 (–)
High: 24% (25/105) High: 0.29* (0.07–0.82)
Luminal PAM50 (luminal vs. other) Luminal: 8% (5/61) 0.16
(\0.001)
0.47*
(0.23–0.93)
Luminal: 0.00 (–)
Other: 36% (20/55) Other: 0.26* (0.06–0.79)
Wound healing (quiescent vs. activated) Quiescent: 7% (2/29) 0.21
(0.02)
0.16*
(0.03–0.51)
Quiescent: 0.00 (–)
Activated: 26% (23/87) Activated: 0.25* (0.06–0.71)
ROR-S (low vs. med/HIGH) Low: 6% (2/32) 0.18
(0.006)
0.22*
(0.05–0.61)
Low: 0.00 (–)
Med/high: 27% (23/84) Med/high: 0.26* (0.06–0.74)
HR hormone receptor, Wt wild type, Mut mutation, ROR-S risk of relapse score, Med medium. * Denotes significant proportional hazard ratio
(likelihood ratio P \ 0.05). A value of 0.00 indicates that there were no recurrences in this category among patients who had a pCR. The
signatures were dichotomized for the purposes of comparison among the signatures. Note that the hazard ratio for the prediction of pCR vs. not is
better within the dichotomized molecular classifications than it is for the population as a whole. The greatest difference in RFS is seen with HR?/
HER2- vs. not (hazard ratio 0.17, [95% CI 0.04–0.51]) which is also where the greatest difference in the rates of pCR were observed (9% vs.
38%). For the dichotomized breast cancer molecular classifiers, the difference between highest and lowest rates of pCR varied from 19 to 29%
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Molecular signatures are currently being used to
identify low risk patients who are less likely to benefit
from chemotherapy regardless of nodal status [35] or in
the setting of HR? node-negative disease [36]. Such
patients have been shown to have low rates of response to
chemotherapy and very low rates of early recurrence [37].
Confirmation of chemotherapy benefit in molecularly low
risk patients will be forthcoming from the TAILORx [38]
and MINDACT [39] trials. In the follow-on I-SPY 2
TRIAL, an adaptive-design neoadjuvant trial to test the
ability of phase 2 agents in combination with chemo-
therapy to increase pCR, 70-gene low risk, HR-positive
and HER2-negative patients are being excluded from
randomization. In I-SPY 1, none of the 11 patients with a
70-gene prognosis profile had a pCR or a recurrence
(Fig. 2).
In the I-SPY cohort, the wound healing signature iden-
tified the largest fraction of low risk patients (based on
RFS) of any signature. The genes consistent with an acti-
vated wound environment characterize women with poor
outcomes, in keeping with increasing evidence that sup-
ports targeting the inflammatory pathway in high risk
cancers [40] and breast cancer in particular [41, 42]. The
activated wound healing signature is associated with poor
outcomes across multiple tumor types and may well reflect
the importance of the microenvironment in tumor behavior.
Although pCR and RCB are very predictive of RFS among
the poor prognosis molecular profiles, the profiles do not
predict an individual patient’s response to standard chemo-
therapy. A substantial fraction of tumors with the highest risk
features have a complete response to therapy and do well,
while others with that same signature have a poor response and
poor outcome. Ongoing analysis is focusing on the I-SPY 1
patients who did not have a complete response to therapy and
had early recurrence, using the described biomarkers as well
as phosphoprotein profiles, to explore targets for future ther-
apeutic intervention.
Our study is limited by the short follow-up time.
Patients with HR-positive tumors continue to be at risk
for recurrence for many years, and early recurrence data
may not reflect the overall outcome [34]. However, in this
select group of patients where almost all patients had
grade 2 or 3 disease, recurrence risk is likely to be con-
centrated in the first 5 years [43]. The Oxford Overview
Analysis of the early breast cancer trials strongly suggests
that the benefit of chemotherapy is reflected by distant
disease-free survival at 5 years, where the survival curves
for patients with chemotherapy versus not initially diverge
but are then parallel, so any survival benefit from che-
motherapy is likely to be manifest in the first 5 years
[44]. The median follow-up period of 3.9 years in the
I-SPY cohort should reflect the benefits in HER-positive
Table 5 Univariate vs. multivariate Cox analyses adjusting for predefined HR/HER2 contribution
Univariate hazard
ratio (95% CI)
Multivariate hazard ratio adjusting for
predefined HR/HER2 contribution (95% CI)
P53 (Wt vs. Mt) 0.33*
(0.16–0.70)
0.46*
(0.22–0.96)
70-Gene (low vs. high) 0.00a
(–)
0.00a
(–)
Luminal PAM50 (luminal vs. other) 0.47*
(0.23–0.94)
0.73
(0.37–1.48)
Wound healing (quiescent vs. activated) 0.16*
(0.04–0.65)
0.20*
(0.05–0.78)
ROR-S (low vs. med/high) 0.22*
(0.07–0.72)
0.29*
(0.09–0.96)
Clinical stage (\stage 3 vs. not) 0.20*
(0.10–0.42)
0.21*
(0.10–0.43)
Ki67 (low/med vs. high) 0.77
(0.42–1.42)
1.14
(0.62–2.10)
Analyses were restricted to the patient subset who did not receive any trastuzumab treatment with known HR/HER2 status, which accounts for
the slight discrepancy between the univariate hazard ratios reported here and Table 4. All signatures were dichotomized (if there were more than
two categories) as follows: HR?/HER2- vs. others, luminal (A and B) vs. other intrinsic subtypes, p53 wild type vs. mutation, 70-gene
prognosis signature low vs. high and wound-quiescent vs.-activated, clinical stage 3 (including inflammatory) vs. earlier stage
* Wald test P \ 0.05
a No events were observed among the 11 patients in the 70-gene low group, which renders the Wald test for significance unreliable
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and triple negative disease, where the risk of recurrence is
early [13].
Molecular and biological heterogeneity were sub-
stantial even within the high risk group of patients in the
I-SPY TRIAL. In this patient cohort, HR and HER2
status were the most predictive of pCR, but the molec-
ular signatures add to the ability of the receptors to
predict RFS. The task that remains is to use current and
emerging markers to identify optimal biological subsets
for new therapeutic agents. Importantly, molecular
marker data should be collected routinely in trials so
that markers and imaging that are early predictors of
outcome can be related to the target endpoint of RFS
[45]. The I-SPY 1 database, with its rich resource of
genomic and protein expression data, is an important
resource to explore emerging and new biomarkers
associated with resistance and response to standard
therapy.
Fig. 2 Stratification, by
molecular classifier, of the
hormone receptor positive
HER2 negative subgroup that
did not achieve a pathologic
complete response. The patients
in the HR?/HER2- subgroup
that did not achieve a pathologic
complete response are stratified
by the molecular subtypes as
shown: a 70-gene prognosis
profile (Blue line low risk/gold
line high risk); b wound healing
signature (Blue line quiescent;
gold line activated); c risk of
relapse subtype score (ROR-S)
(Blue line low risk/Gold line
medium and high risk); d p53
predicted mutation (Blue line
predicted wild type/Gold line
predicted mutation); e clinical
stage (Blue line clinical stage 2/
Gold line clinical stage 3).
Stratification of the ‘‘no pCR’’
HR?/HER2- patient group by
molecular signatures and
clinical stage
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